Lithium Carbonate Shortage: What Providers and Prescribers Need to Know in 2026

Lithium carbonate has maintained a remarkably stable national supply since its FDA approval in 1970, and as of 2026, it remains off the FDA Drug Shortages Database. However, clinicians regularly encounter patients who cannot fill their specific formulation or strength locally. This guide provides a clinical framework for understanding why, what to tell patients, and how to manage the cases where a formulation genuinely becomes unavailable.

Current Shortage Status (2026)

As of early 2026, lithium carbonate is not listed in the FDA Drug Shortages Database. The generic market remains robust with multiple approved manufacturers. However, prescribers should be aware of the following nuances:

No national shortage declared. Standard 300 mg tablets and capsules are widely available at most pharmacies.

Formulation-level gaps exist. The 150 mg capsule, 450 mg ER tablet, and oral solution are stocked at fewer pharmacies and may require advance ordering or transfer.

Brand-name Lithobid. While technically still available, many chain pharmacies stock only the generic ER formulation. Patients with "Lithobid" on their prescription may be surprised to receive a different-looking tablet.

Clinical Considerations Unique to Lithium's Narrow Therapeutic Index

Lithium's narrow therapeutic index (therapeutic range: 0.8–1.2 mEq/L for acute mania; 0.6–1.2 mEq/L for maintenance; toxic threshold: ≥1.5 mEq/L) creates clinical constraints that do not apply to most other medications:

IR ↔ ER substitution is not straightforward. Immediate-release (IR) and extended-release (ER) formulations have different absorption profiles and peak concentrations. Switching between them requires dose adjustment and repeat serum level monitoring. Patients should be counseled not to accept a different formulation without prescriber authorization.

Manufacturer-to-manufacturer substitution is generally acceptable. All FDA-approved generic lithium carbonate tablets/capsules are AB-rated. Unlike some narrow therapeutic index drugs (e.g., levothyroxine), prescriber guidance does not universally require same-manufacturer dispensing for lithium, though some clinicians prefer consistency.

Renal and dietary changes affect levels. Patients who are dehydrated, on a low-sodium diet, or taking NSAIDs/ACE inhibitors/diuretics are at elevated risk of toxicity even at previously stable doses. Educate patients to contact you before starting any new OTC NSAID.

Monitoring Requirements That Can Affect Prescription Access

One of the most common reasons patients perceive a 'shortage' is actually a monitoring-related refill delay. Standard monitoring for patients on maintenance lithium includes:

Serum lithium levels: Every 2–3 months during maintenance once stable; 12 hours post-dose (trough) for accurate measurement

Renal function: SCr, BUN, eGFR every 6 months; lithium-induced nephropathy risk increases with duration of therapy

Thyroid function: TSH every 6–12 months; hypothyroidism occurs in up to 40% of long-term lithium patients

Serum calcium: Annually; lithium-induced hypercalcemia and hyperparathyroidism are underrecognized

When a patient's labs are overdue, it is clinically appropriate to hold or limit refills pending updated results. Proactively reminding patients to schedule labs before their prescription runs out can prevent unnecessary access gaps.

If a Patient Cannot Find Their Formulation: Clinical Guidance

If a patient contacts your office because they cannot find their specific Lithium Carbonate formulation, a stepwise approach:

Verify it is a localized issue: Check the FDA database. If it's not listed as a shortage, direct patient to call additional pharmacies or use medfinder.com.

Provide a bridge prescription: If the patient has only a few days of medication left, authorize a short bridge supply at their closest pharmacy with any available formulation (with appropriate dosing guidance).

Formulation-switch guidance (IR ↔ ER): If the only available option is a different formulation, calculate equivalent dosing (lithium carbonate 300 mg IR TID is approximately equivalent to 450 mg ER BID; verify with current labeling), obtain a new lithium level 3–5 days after switch, and watch for early toxicity signs.

Compounding as last resort: For unusual doses (pediatric, elderly requiring <150 mg), a compounding pharmacy can prepare custom concentrations. This is rarely necessary for standard adult doses.

When a True Shortage Occurs: Clinical Alternatives

If a genuine, sustained supply disruption were to occur, guideline-supported alternatives for bipolar maintenance include:

Valproate/divalproex sodium (Depakote): FDA-approved for acute mania and maintenance; first-line alternative; comparable efficacy in mania prevention; avoid in women of childbearing potential due to teratogenicity.

Quetiapine (Seroquel/Seroquel XR): FDA-approved for maintenance; effective for both mania and depression prevention; significant sedation and metabolic side effects.

Lamotrigine (Lamictal): FDA-approved for bipolar maintenance; best for depression-predominant bipolar; requires 8+ week titration; not suitable for acute mania.

Aripiprazole (Abilify): FDA-approved for acute mania and maintenance (adjunct to lithium or valproate); favorable metabolic profile.

Key clinical note: Lithium has a unique anti-suicidal effect (reducing suicides approximately 9-fold) that is not replicated by any of these alternatives. This must be factored into the risk-benefit analysis before transitioning high-risk patients away from lithium.

For a practical patient-access workflow, see How to Help Your Patients Find Lithium Carbonate in Stock: A Provider's Guide. Providers can also use medfinder for Providers to help patients locate their medications in stock.